Physician profile
Mark B Sacher
NPI 1679567812
$4,747.96
in general payments reported to CMS, 2019-2025
27 companies · $751 in 2025
The $751 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $192 · 2021: $851 · 2022: $640 · 2023: $821 · 2024: $818 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,390.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $822.88 | 2021-2025 | Qulipta, Ubrelvy |
| Collegium Pharmaceutical, INC. | $772.64 | 2019-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $650.36 | 2019-2024 | Ztlido |
| Pfizer INC. | $582.22 | 2019-2025 | |
| Orexo US, INC. | $575.78 | 2019-2025 | Zubsolv |
| Biodelivery Sciences International, INC. | $194.60 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $148.27 | 2022 | |
| Medtronic, INC. | $140.34 | 2021 | |
| Acelrx Pharmaceuticals, INC. | $113.51 | 2019 | |
| Indivior INC. | $96.51 | 2020-2025 | Sublocade |
| Protega Pharmaceutials INC | $94.78 | 2023-2025 | Roxybond |
| Virtus Pharmaceuticals LLC | $74.37 | 2021 | |
| Daiichi Sankyo INC. | $66.14 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.19 | 2021-2025 | Relistor |
| Almatica Pharma LLC | $42.19 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $37.18 | 2022 | |
| Idorsia Pharmaceuticals US INC | $36.84 | 2022-2023 | Quviviq |
| Uswm, LLC | $34.74 | 2021 | |
| Averitas Pharma INC. | $31.36 | 2025 | Qutenza |
| Radius Health, INC. | $30.47 | 2019 | |
| Bioventus LLC | $28.84 | 2021 | |
| Braeburn INC. | $27.50 | 2025 | Brixadi |
| Biotronik Nro, INC. | $22.59 | 2025 | Prospera |
| Lilly USA, LLC | $19.31 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $16.79 | 2024 | |
| Lundbeck LLC | $15.67 | 2022 | |
| Amgen INC. | $14.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sacher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.